Publication
Retrospective analysis of sorafenib as first- or second-line targeted therapy in patients with mRCC: Three-year Italian experience.
Giuseppe Procopio, Lisa Derosa, Angela Gernone, Franco Morelli, Teodoro Sava, Vittorina Zagonel, Ugo De Giorgi, Vittorio D. Ferrari, Cristina Masini, Donatello Gasparro, Alessandra Felici, Rossana Berardi, Nicola Calvani, Giovanni Lo Re, Helga Lipari, Maria Pia Brizzi, Michele Sisani, Camillo Porta, Enzo Galligioni, Antonio Silverio Contu
Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2013.31.6_suppl.415